You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 30, 2025

Claims for Patent: 6,290,961

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,290,961

Title:	Method for treating dystonia with botulinum toxin type B
Abstract:	A method and composition for treating a patient, suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
Inventor(s):	Aoki; K. Roger (Laguna Hill, CA), Grayston; Michael W. (Irvine, CA), Carlson; Steven R. (Laguna Niguel, CA), Leon; Judith M. (Laguna Niguel, CA)
Assignee:	Allergan, Inc. (Irvine, CA)
Application Number:	09/490,756
Patent Claims:	1. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of botulinum toxin type B under time and conditions to treat cervical dystonia. 2. The method of claim 1, wherein the botulinum toxin type B is administered by intramuscular injection. 3. The method of claim 1, wherein the administration of the botulinum toxin type B results in an alleviation of a symptom of the cervical dystonia within about 1 day to about 7 days. 4. The method of claim 1, wherein the patient is administered at least about 50 units of the botulinum toxin type B. 5. The method of claim 1, wherein the patient is administered at least about 1,000 units of the botulinum toxin type B. 6. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of botulinum toxin type B under time and conditions to treat cervical dystonia, wherein the botulinum toxin type B is administered by intramuscular injection, the administration of the botulinum toxin type B results in an alleviation of a symptom of the cervical dystonia within about 1 day to about 7 days and the patient is administered at least about 1,000 units of the botulinum toxin type B. 7. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of botulinum toxin type B, thereby reducing the severity of an abnormal head position symptom of cervical dystonia. 8. A method for treating cervical dystonia, the method comprising the step of administering to a human patient an effective amount of botulinum toxin type B, thereby reducing a neck pain symptom of cervical dystonia.

Details for Patent 6,290,961

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Solstice Neurosciences, Llc	MYOBLOC	rimabotulinumtoxinb	Injection	103846	December 08, 2000	⤷ Get Started Free	2020-01-24
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	May 07, 2001	⤷ Get Started Free	2020-01-24
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	November 14, 2014	⤷ Get Started Free	2020-01-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 6,290,961

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	9517904	⤷ Get Started Free
United States of America	8557256	⤷ Get Started Free
United States of America	8486886	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.